Nascobal

(Cyanocobalamin)

Phase 3Small molecule

GGrupo Espanol de Tumores Neuroendocrinos

Nascobal is one of 29 small molecule programs targeting Stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

StrokePhase 3

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

Nascobal

GGrupo Espanol de Tumores Neuroendocrinos

Phase 3

1 2

Activase

Roche

Preclinical

19 3

Zometa

Pfizer

Preclinical

1 4

Folvite

Eli Lilly

Preclinical

1 5

Botox

RRevance Therapeutics, Inc.

Preclinical

2 6

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Alka-Seltzer

AAbbott

Preclinical

1 8

Inderal

Mylan Pharmaceuticals Inc

Botulinum Toxin a

1 10

Anticoagulants

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2/3Recruiting

Study completion

NCT05005897

Phase 3Not yet recruiting

Clinical Trial

NCT06966856

Clinical

Trials by Indication[1]

HIV-Infected Individuals1 trial

Effect of Vitamin B on Plasma Neurofilament Light Protein (NFL) in HIV-infected Individuals With Increased Plasma Homocysteine

Unknown status·GGöteborg University·Phase 2·NCT02773147·60 enrolled

GLP-11 trial

GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response

Completed·TThe University of Texas Health Science Center, Houston·Phase 4·NCT04387201·23 enrolled

Clinical Trial1 trial

This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcting Early-onset Vitamin B12 Deficiency in Adult Patients Using Proton Pump Inhibitors (PPIs). The Primary Outcome is the Change in Serum Vitamin B12 Levels Over a 6-week

Not yet recruiting·TTanta University·Phase 3·NCT06966856·23 enrolled

Treatment1 trial

Effects of Vitamin B12 Treatment in Singers

Completed·UUniversity of Southern California·Phase 1·NCT03437824·20 enrolled

Oral1 trial

Oral Cyanocobalamin (Eligen B12) Bioavailability Study

Completed·EEmisphere Technologies, Inc.·N/A·NCT01311739·20 enrolled

3 more indications

Stroke1 trial

Vitamin Therapy for Prevention of Stroke

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 3·NCT00004734

End-Stage Renal Disease1 trial

Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis

Completed·GGeorgetown University·N/A·NCT00004495·84 enrolled

Unspecified1 trial

Early Infant Micronutrition and Development

Recruiting·SSykehuset Innlandet HF·Phase 2/3·NCT05005897·600 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

REDISOL

NDA NDA006668

Jan 1, 1982

RUBIVITE

NDA NDA010791

Jan 1, 1982

RUBRAMIN PC

NDA NDA006799

Jan 1, 1982

VI-TWEL

NDA NDA007012

Jan 1, 1982

CYANOCOBALAMIN

NDA NDA007085

Jan 1, 1982

BERUBIGEN

NDA NDA006798

Nov 5, 1996

NASCOBAL

NDA NDA019722

Jan 31, 2005

NASCOBAL

NDA NDA021642

Jul 27, 2007

CALOMIST

NDA NDA022102

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Cyanocobalamin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cyanocobalamin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cyanocobalamin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA022102). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Grupo Espanol de Tumores Neuroendocrinos company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGrupo Espanol de Tumores Neuroendocrinos

Nascobal

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

HIV-Infected Individuals1 trial

GLP-11 trial

Clinical Trial1 trial

Treatment1 trial

Oral1 trial

Stroke1 trial

End-Stage Renal Disease1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News